Randomized Polypill crossover trial in people aged 50 and over. - Wikidata - wikimedia - TriplyDB

Randomized Polypill crossover trial in people aged 50 and over.

Randomized Polypill crossover trial in people aged 50 and over.

http://www.wikidata.org/entity/Q34345933

about

Fixed-dose combination therapy for the prevention of cardiovascular disease Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill Resource Effective Strategies to Prevent and Treat Cardiovascular Disease Historical perspective of traditional indigenous medical practices: the current renaissance and conservation of herbal resources Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example.Prehypertension: Underlying pathology and therapeutic options.The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials.Randomised trial of text messaging on adherence to cardiovascular preventive treatment (INTERACT trial).Assessing population aging and disability in sub-Saharan Africa: lessons from Malawi?Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China.[Management of different cardiovascular risk factors with a combination tablet (polypill)].Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?Starting the polypill: the use of a single age cut-off in males and females.Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement.Effect of Pollypill on cardiovascular parameters: Systematic review and meta-analysis.Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.Integrated preclinical cardiovascular prevention: a new paradigm to face growing challenges of cardiovascular disease.Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation.Polypills for the prevention of Cardiovascular diseases.Expert opinion: the therapeutic challenges faced by statin intolerance.Testing equality and interval estimation in binary responses when high dose cannot be used first under a three-period crossover design.The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.The polypill and the prevention of heart attacks and strokes by Caroline Telfer.Polypill treatments for cardiovascular diseases.Stroke Minimization through Additive Anti-atherosclerotic Agents in Routine Treatment (SMAART): study protocol for a randomized controlled trial.Drugs: Blood battles

P2860

Q24195065-78BEA1A0-8742-456E-A8D0-3761F080D902 Q26753102-5A219301-2543-4AB4-A2CD-6F187B1DBCAA Q26768304-E6111C46-E391-42E1-AA61-F3157A52C19B Q28657343-0304D005-9CF4-4F4F-B0F1-5683E93E4C76 Q30235416-268FD663-FB16-4D92-B861-1B7D683F83FB Q33581084-4658EC7D-47F5-4797-8820-06E03F075002 Q34161787-79F8E16D-3862-473A-A9CB-EADD36973EF8 Q34179007-A425BBF7-F609-4ECE-B7EE-9C5A4A232308 Q34533125-4C3ABDDB-8835-4D79-B986-E19D94E6360B Q34640952-7411F1EE-8D34-410A-8FAA-DF12BDB819AA Q34722470-5B01A863-A394-4E89-8039-8D858ED0A149 Q36013827-6CD30034-0F05-48FE-AC05-64644EACADD9 Q36322893-F9CC00F8-8A85-41B0-86E1-1A7734C0D95E Q36928081-018A6545-0808-469E-9C34-249011E1735C Q37077196-476682D7-1C79-4983-909C-062579EE5585 Q37641217-A2E8DF35-306B-46B6-98E8-2FA12B6A7E96 Q38079763-D8A74409-9222-423F-8BE5-D9E92AEA8FAF Q38136621-BC6E03B7-3E3D-4C1E-85A5-A67560CED4D0 Q38394893-0B8A85DB-E46A-4192-948D-2832B7BC2CF6 Q38430611-7496E1F8-698F-44DC-98FF-A10C5D07DE7E Q38615230-F8219EBA-DF51-4F55-BBF9-9A45C0A0145B Q38809466-9D9AAF31-60FE-45AE-92DD-7E698D5D7F8A Q38851603-8FF4AE8D-CDDB-48D5-90C0-C17301F21D0E Q39206963-A5389ABA-70A4-493F-BF9A-D1FF1D407FF6 Q39231217-45A0A812-0E0C-447D-A4E0-DFA077FCEDF1 Q41617873-E74478BA-C453-4ECF-BBC0-8F9135E7F6E1 Q46458045-0CD702E5-0FC2-41C2-A43A-6F21040084A1 Q50913648-65B38412-FDEB-4AB4-B817-0111BA0A0D11 Q51740192-D929AA07-3B77-4A88-B335-30C353F4896E Q74441269-91145E15-5A7D-4405-AABF-160F1A519E5F

P2860

Randomized Polypill crossover trial in people aged 50 and over.

http://www.wikidata.org/entity/Q34345933

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Randomized Polypill crossover trial in people aged 50 and over.

@ast

Randomized Polypill crossover trial in people aged 50 and over.

@en

Randomized Polypill crossover trial in people aged 50 and over.

@nl

type

label

Randomized Polypill crossover trial in people aged 50 and over.

@ast

Randomized Polypill crossover trial in people aged 50 and over.

@en

Randomized Polypill crossover trial in people aged 50 and over.

@nl

prefLabel

Randomized Polypill crossover trial in people aged 50 and over.

@ast

Randomized Polypill crossover trial in people aged 50 and over.

@en

Randomized Polypill crossover trial in people aged 50 and over.

@nl

P1433

Q34345933-A8F18186-D7AD-4F15-BF88-A0A92CA0E978

P1476

Q34345933-5CE35AFF-731A-42B0-9C3E-458353B4F705

P2093

Q34345933-B6E98581-F027-4FB3-9AF9-B2D388477A66

Q34345933-BB8C880D-9E52-4593-8836-E87791286D15

P2860

Q34345933-10B12C71-8022-451D-B40B-FC454D50184D

Q34345933-27005657-6AE7-4C8D-9817-365F3E7786F6

Q34345933-279F121B-AA18-4472-BB0D-C31D0FDE94E5

Q34345933-341DD40C-6397-4BEC-B666-CD2C2FE847DF

Q34345933-45D9DA9F-634B-4248-82F8-25A61ACC83BB

Q34345933-46C37120-6520-4E5D-B60B-602F7A4006F1

Q34345933-496064EB-1BE9-4DE7-B5C7-24E07FCE2EC4

Q34345933-5AB0CEE5-21BD-4919-B6B7-F29C29A761E1

Q34345933-794E45DA-76C7-4885-86BC-BB8065E93A12

Q34345933-8CBAA2F2-7E21-49DC-B017-816FDB3DB018

P304

Q34345933-1F57F6C3-7A32-4BD7-AAC9-FB5EEC3A221F

P31

Q34345933-F657E2EA-9443-41AA-93BC-C0DE744A05C6

P356

Q34345933-B570518E-BE25-4C6A-87DD-F0A6D231F259

P407

Q34345933-9D3C2A09-699B-4C4F-BB1E-298386EC25ED

P433

Q34345933-361C40E6-BC12-45E1-B3E2-473B6BFD2FC9

P478

Q34345933-0E7C3BE1-029C-48A7-A98C-91EE7EF6723F

P50

Q34345933-B226E224-253D-4194-9FD7-FC9922CE3477

P577

Q34345933-D6C07F2E-2BA9-483D-BFBE-F7B6BAB51CFA

P5875

Q34345933-E4515CE6-8E4C-4022-AB1B-DA6E423D01D1

P698

Q34345933-CF08ACA7-655C-4085-B568-D28134275A30

P932

Q34345933-8BF90537-B924-4008-BF47-77E041A68ECF

P356

JOURNAL.PONE.0041297

P1433

P1476

Randomized Polypill crossover trial in people aged 50 and over.

@en

P2093

David S Wald

http://www.w3.org/2001/XMLSchema#string

Nicholas J Wald

http://www.w3.org/2001/XMLSchema#string

P2860

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

A strategy to reduce cardiovascular disease by more than 80%

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

Screening for future cardiovascular disease using age alone compared with multiple risk factors and age

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening.

P304

e41297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0041297

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229427991

http://www.w3.org/2001/XMLSchema#string

P698

22815989

http://www.w3.org/2001/XMLSchema#string

P932

3399742

http://www.w3.org/2001/XMLSchema#string